Redefining Combination Cancer Therapy with Precision Shielding
At GEAR Biosciences, we employ precision genetic editing to generate NK cell therapies that are GEARed towards enhancing the therapeutic activity of cancer therapy.
About GEAR
We are a Pittsburgh, PA-based biotechnology company developing next generation therapies and diagnostics to improve outcomes for patients with hematological diseases.
What Do We Do?
Augmenting Therapeutic Activity of mAbs
Therapeutic monoclonal antibodies (mAbs) have become a staple of immunotherapy. Our GEAR-NK cell therapies are geared toward boosting the therapeutic activity of several FDA-approved mAbs to improve patient outcomes across a variety of hematological indications.
How Do We Do It?
Our Technology
With the power of precision genetic editing technology, we precisely engineer donor-derived NK cells, endowing them with resistance to antibody-mediated “fratricide”. Each GEAR-NK platform is meticulously crafted to boost the therapeutic activity of a specific monoclonal antibody (mAb). We are initially focusing on CD38-associated cancers such as MM, AML, and ALL, but have plans to expand to other hematological indications including autoimmunity.
Our CD38 diagnostic is a simple PCR-based genetic test that can predict patient response to CD38 monoclonal antibodies. This in vitro screening tool is designed to be used prior to initiation of mAb therapy, and provide a quick and easy way to achieve accurate, meaningful insights that enable more cost-effective, patient-oriented, data-driven medical decisions.
Our Goals
- Develop novel therapeutics
- Improve patient outcomes
- Disrupt industry norms
- Revolutionize cancer therapy
What Are We Up To?
Recent News and Events
Presentations
Recent News
Check back soon for updates.